142 related articles for article (PubMed ID: 16863481)
1. Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.
Robertson SM; Formentini E; Alfaro RM; Falloon J; Penzak SR
Pharmacotherapy; 2006 Aug; 26(8):1051-9. PubMed ID: 16863481
[TBL] [Abstract][Full Text] [Related]
2. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
3. Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.
Robertson SM; Formentini E; Alfaro RM; Natarajan V; Falloon J; Penzak SR
Br J Clin Pharmacol; 2006 Apr; 61(4):379-88. PubMed ID: 16542198
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
5. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
8. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
[TBL] [Abstract][Full Text] [Related]
10. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
11. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
Lowry JA; Kearns GL; Abdel-Rahman SM; Nafziger AN; Khan IS; Kashuba AD; Schuetz EG; Bertino JS; van den Anker JN; Leeder JS
Clin Pharmacol Ther; 2003 Mar; 73(3):209-22. PubMed ID: 12621386
[TBL] [Abstract][Full Text] [Related]
12. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
13. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
14. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
Solas C; Simon N; Drogoul MP; Quaranta S; Frixon-Marin V; Bourgarel-Rey V; Brunet C; Gastaut JA; Durand A; Lacarelle B; Poizot-Martin I
Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
[TBL] [Abstract][Full Text] [Related]
15. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Fitzsimmons ME; Collins JM
Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
[TBL] [Abstract][Full Text] [Related]
16. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
17. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
18. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
[TBL] [Abstract][Full Text] [Related]
19. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
20. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
